PO.BCS01.13 · 生物信息与计算

化疗对癌细胞结构的重塑

Remodeling of cancer cell architecture by chemotherapy

海报缩略图:化疗对癌细胞结构的重塑
编号 6902 展板 15 时间 4/22 09:00–12:00 区域 Section 4 主讲 Gege Qian, BS;MS;PhD
分会场 New Algorithms and Computational Methods
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Gege Qian1, Xiaoyu Zhao2, Leah V. Schaffer3, Kyung-Mee Moon2, Jiahao Gao2, Emma Lundberg4, Leonard Foster2, Trey Ideker5

1UC San Diego School of Medicine, La Jolla, CA,23University of California San Diego - UCSD, San Diego, CA,4Schools of Engineering and Medicine, Stanford University, Stanford, CA,5UC San Diego, La Jolla, CA

摘要 Abstract

中文摘要
化疗如何重塑肿瘤细胞——以及这些变化如何影响耐药性等结局——在很大程度上仍不清楚。在此,我们对肿瘤亚细胞组织及其被化疗重组的情况进行了多模态、全局性的表征。我们使用自监督学习来编码四种正交数据模态中的蛋白质坐标:全蛋白质组尺寸排阻色谱分级(在使用顺铂或伏立诺他治疗前后)、天然状态免疫荧光成像、亲和纯化,以及覆盖7,579种蛋白质的一级序列信息。这一整合图谱解析了174个亚细胞组分,涵盖从蛋白质复合物到细胞器的分子组装体,尺寸范围约为10-9至10-5 nm。58个组分在治疗后经历了显著重塑,重现了已知的作用机制,并揭示了此前未被认识的通路改变,如细胞骨架组织和代谢重编程。我们使用全基因组CRISPR敲除药物敏感性分析系统地验证了这些“化疗响应组装体”,识别出哪些组装体赋予药物敏感性还是耐药性。经化疗重塑的组分作为预测治疗响应的癌症突变的汇聚点——包括那些参与同源重组修复、染色质重塑和双链断裂修复的突变。
查看英文原文 English abstract
How chemotherapy reshapes tumor cells-and how these changes influence outcomes such as drug resistance-remains largely unclear. Here, we present a multimodal, global characterization of tumor subcellular organization and its reorganization by chemotherapy. We use self-supervised learning to encode protein coordinates across four orthogonal data modalities: proteome-wide size-exclusion chromatography fractionation (before and after treatment with cisplatin or vorinostat), native-state immunofluorescence imaging, affinity purification, and primary sequence information covering 7,579 proteins. This integrated map resolves 174 subcellular components, spanning molecular assemblies from protein complexes to organelles across a size range of ~10-9 to10-5nm. 58 components undergo significant remodeling upon treatment, recapitulating known mechanisms of action and revealing previously unrecognized alterations in pathways such as cytoskeletal organization and metabolic rewiring. We systematically validate these “chemotherapy-response assemblies” using genome-wide CRISPR knockout drug-sensitivity profiling, identifying which assemblies confer drug sensitivity versus resistance. Chemotherapy-remodeled components serve as convergence points for cancer mutations that predict therapeutic response-including those involved in homologous recombination repair, chromatin remodeling, and double-strand break repair.
利益披露 Disclosure
G. Qian, None.

← 返回 AACR 2026 检索